Market Overview
According to Fortune Business Insights, the global uveitis therapeutics market size was valued at USD 2.71 billion in 2025. The market is projected to grow from USD 2.96 billion in 2026 to USD 6.00 billion by 2034, exhibiting a CAGR of 9.23% during the forecast period. North America is projected to dominate the uveitis therapeutics market during the forecast period.
Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Uveitis Therapeutics Market, 2026-2034.”
The analysis shows that the market is witnessing significant momentum due to the rising incidence of ocular inflammatory conditions and the introduction of targeted monoclonal antibodies. For example, according to the Northern California Epidemiology Study, around 1.5 per 100,000 population are affected by intermediate uveitis each year, while the condition as a whole mostly affects individuals aged 20 to 40 years old. This trend, alongside new biologic approvals, indicates a strong demand for uveitis therapeutics worldwide.
Major Players Profiled in the Market Report:
Segments
High Prevalence in Western Countries to Propel Anterior Uveitis Segment Growth
Based on uveitis type, the market is divided into anterior, intermediate, posterior, and panuveitis. The anterior uveitis segment (where inflammation is seen in the iris and ciliary body) is the most common form of uveitis observed in Western countries, driving significant treatment demand across the market.
High Safety and Efficacy of Biologics to Drive Immunosuppressive Medications Segment Expansion
By drug class, the market is categorized into anti-inflammatory medications, antibiotic and antivirals, immunosuppressive medications, and others. While corticosteroids are considered the first line of therapy, the immunosuppressive medications segment (which includes biologics) is anticipated to significantly enhance market growth during the forecast period, as these drugs are considered safer and more effective for long-term management.